Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Stem cells · 1 trial · 1 indication
Total number of Adverse Events and Severe Adverse Events, related and non-related with the medication will be recorded as a measure of tolerability and safety.
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | 1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15 2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15 3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15 |
| Placebo | PLACEBO_COMPARATOR | Lactate Ringer´s solution |
| Name | Type | Description |
|---|---|---|
| Stem cells | GENETIC | 1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15 2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15 3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15 |
| Placebo | GENETIC | 1. first cohort: 20 ml administered at days 1, 8 and 15 2. second cohort: 40 ml administered at days 1, 8 and 15 3. third cohort: 80 ml administered at days 1, 8 and 15 |
Inclusion criteria Patients must meet all the following inclusion criteria to be eligible for study entry: 1. Must understand and voluntarily sign an informed consent form prior to the conduct of any study related assessment/procedures. 2. Subjects with RA under treatment with at least one non-bio...
Takeda Pharmaceutical Company Limited is developing a stem cell therapy for rheumatoid arthritis aggravated, an inflammatory joint condition. The program is in Phase 1 clinical development as a cell therapy in the immunology therapeutic area. It is an investigational treatment and has not been approved for commercial use.
Takeda Pharmaceutical Company Limited, which trades under the ticker TAK, is the developer of this stem cell therapy for rheumatoid arthritis aggravated. The program is in Phase 1 and is being studied as a cell therapy in the immunology therapeutic area.
Takeda's stem cell therapy for rheumatoid arthritis aggravated is in Phase 1 clinical development. It is an investigational cell therapy and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed.
The stem cell therapy has been evaluated in one completed Phase 1 trial, NCT01663116, titled Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients. The trial enrolled 53 participants in Spain, was randomized and placebo-controlled, and included adults 18 years and older of all sexes.
Takeda's stem cell therapy is an investigational cell therapy being studied for rheumatoid arthritis aggravated. It is designed to be administered intravenously, as reflected in the completed Phase 1 trial NCT01663116. The specific molecular target or mechanism of action has not been disclosed.